Articles tagged with Glioblastomas
Christina Tringides' CHAMELEON project aims to develop soft, sensor-laden brain implants that can monitor and treat glioblastoma with greater precision. Her lab creates hydrogel-based arrays with conductive electrodes to track neural signals in real-time.
Researchers at Mass General Brigham developed a modified herpes simplex virus that stimulates the immune system to attack glioblastoma cells, increasing T-cell and natural killer cell responses. The virus, engineered to recognize markers found on glioblastoma cells, also increases overall survival in preclinical models.
Researchers at the University of Plymouth will receive a £2.8 million funding boost to accelerate new treatments for low-grade brain tumors. The center aims to deepen understanding and translate knowledge into life-changing therapies.
A clinical trial found a nearly 40% increase in overall survival for glioblastoma patients treated with focused ultrasound and chemotherapy. The study also showed that liquid biopsy tests can detect cancer biomarkers, which are closely concordant with patient outcomes.
Researchers developed a noninvasive approach using nasal drops to deliver potent tumor-fighting medicine to the brain, boosting the immune response and eradicating glioblastoma tumors in mice. The nano-sized medicine successfully activated the STING pathway and armed the immune system to fight the cancer.
A team at the University of Pennsylvania has solved the mechanism of action of hydralazine, revealing its potential to halt the growth of brain cancer cells. By blocking an oxygen-sensing enzyme, hydralazine can reduce intracellular calcium levels, causing blood vessels to relax and tumor cells to enter a dormant state.
Research highlights the role of ATAD2 in promoting glioma progression by co-activating PDK1 with E2F1, leading to poorer prognoses in patients. A personalized prognostic nomogram using CTARS has been developed for predicting clinical outcomes.
Researchers have discovered that ATAD2 promotes glioma progression by working with E2F1 to activate PDK1. The study also found that high levels of ATAD2 are associated with poorer outcomes in glioma patients.
Researchers found that lower LRIG1 expression is linked to more aggressive gliomas, a type of brain tumor. The study suggests that LRIG1 could serve as a useful marker for tumor severity and potentially as a target for future therapies.
Glioblastoma's unique defenses hinder CAR-T cell efficacy due to antigenic heterogeneity and immunosuppressive tumor microenvironment. Novel strategies, including multi-target and logic-gated CARs, switchable and universal CARs, and combination therapies, aim to breach these barriers and reprogram the immune system.
Researchers developed a biodegradable implant that slowly releases drugs to myeloid cells, waking up the immune system to fight cancer. The approach prevented tumor recurrence in over half of mice and showed promising results in human samples.
Epithelial-mesenchymal transition (EMT) is a key driver of glioblastoma progression and therapy resistance. Emerging strategies to disrupt EMT signaling, such as natural compounds and small-molecule inhibitors, hold promise for reducing tumor invasion and enhancing sensitivity to standard therapies.
Researchers have developed a novel treatment approach using amplitude-modulated radiofrequency electromagnetic fields to slow glioblastoma cell growth and target tumor stem cells. The therapy shows promise in both laboratory experiments and clinical trials with two patients, demonstrating potential for treating brain cancer.
Researchers create novel antibody-based treatment that combines diagnostic and therapeutic capabilities to target LRRC15-expressing tumors, slowing growth and extending survival. The approach shows promise in preclinical models by priming tumors for immune response and boosting immunotherapy's effectiveness.
A multi-institutional study found that serially testing tumor samples can detect immune system activation in recurrent glioblastoma even when traditional imaging measures cannot. The researchers used multi-omic analysis and integrated data from various sources to show positive changes in the tumor microenvironment over time.
The proton therapy cohort of NRG-BN001 demonstrated improved overall survival (OS) for patients with newly diagnosed glioblastoma, with a 6.8% absolute survival advantage at 2 years. The results support the development of a phase III randomized trial to confirm these findings.
A new study decodes the mechanism of glioblastoma's resistance to chemotherapy by identifying a HIF-independent circuit built around the epigenetic enzyme PRMT2. Researchers found that combining an existing orphan drug with standard chemotherapy can overcome this resistance, doubling survival without added toxicity.
Researchers identified Wnt7b as a determinant of resistance to immune checkpoint blockers in glioblastoma and developed a combination therapy with WNT974 that sensitizes GBM to anti-PD1 therapy, improving anti-tumor immunity. This approach offers a promising new therapeutic avenue for glioblastoma patients.
Virginia Tech researchers create method combining MRI, fluid dynamics, and algorithm to identify hidden glioblastoma cells. The technique uses fluid flow patterns to predict tumor re-growth, allowing for more aggressive surgical approaches. This technology has potential to improve cancer treatment outcomes
A team of scientists has identified rogue DNA rings as early drivers of glioblastoma growth, suggesting a window of opportunity for earlier detection and treatment. The study suggests that targeting these DNA rings could lead to more effective treatments.
Scientists have found a way to stop brain cancer cells from spreading by 'freezing' hyaluronic acid molecules in place. This approach could lead to a new type of treatment for glioblastoma, the most aggressive form of brain cancer.
Researchers from the University of Maryland School of Medicine have developed a reliable measurement for opening the blood-brain barrier using focused ultrasound. By analyzing acoustic emissions signals generated by circulating microbubbles, they found that this method can predict blood-brain barrier opening in patients with glioblasto...
The Ellen Siow Professorship aims to advance education and research in neuro-oncology, specifically glioblastoma. This will drive the development of innovative programmes and interventions, fostering progress that benefits people in Singapore and beyond.
Researchers at UCL discovered that blocking brain damage triggered by glioblastomas can slow cancer growth and maintain normal brain function. The study found that early-stage tumours damaged axons, accelerating tumor growth, but deactivating SARM1 slowed tumor progression.
Researchers identify B-cell lymphoma 6 (BCL6) as a key player in promoting glioma cell proliferation and progression. A novel small-molecule inhibitor YK01 targets BCL6, showing potent anti-tumor effects in GBM cells and animal models.
The NRG-BN007 clinical trial found that combining ipilimumab and nivolumab with radiation therapy did not improve progression-free survival for patients with newly diagnosed MGMT-unmethylated glioblastoma. The treatment combination showed no significant difference in overall survival either.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
Researchers Sontheimer and Monje have made groundbreaking discoveries in brain tumor growth, revealing how nerve cells promote the development of aggressive gliomas. Their work has laid the foundation for new treatments and clinical trials, offering hope for innovative therapies.
Gene coexpression analysis reveals optimal markers of cell types and states, providing opportunities for developing novel biomarkers and targeted treatment strategies for glioma patients. Dr. Oldham's work tackles the reproducibility crisis in science, emphasizing data metadata standardization.
Researchers highlight the benefits of artificial intelligence in glioblastoma management, including improved diagnosis, treatment planning, and personalized therapy. AI-based models can analyze radiological images, predict tumor characteristics, and suggest effective treatments, promising to improve patient outcomes and survival rates.
A new cytokine delivery platform reprograms the tumor microenvironment to enhance CAR-T cell function in preclinical brain cancer models. The strategy leads to a broader immune response that inhibits tumor growth and extends host survival, even in mice with only a fraction of cells expressing the CAR-targeted antigen.
Researchers developed a technique to measure brain tumors' mechanical force, distinguishing between tumors that push against the brain or invade surrounding tissue. This measurement can help clinicians inform patient strategies to alleviate symptoms and predict outcomes of chemotherapy and immunotherapy.
Researchers create a potential treatment for glioblastoma, called MT-125, that makes malignant cells responsive to radiation and chemotherapy. The compound also blocks the cancer's ability to invade other tissue and has shown promise in animal studies.
Researchers at Florida Atlantic University have secured two key grants to investigate targeting the MBLAC1 gene as a new approach to treat glioblastoma, a very aggressive and fast-growing type of brain cancer. The project aims to advance innovative projects that could make a meaningful impact on cancer therapy.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
A new molecule called the 'Fusion Superkine' has been created to target and kill glioblastoma cells while stimulating an immune response to prevent recurrence. The treatment, developed by VCU Massey Comprehensive Cancer Center researchers, uses a combination of immunotherapy and targeted delivery to overcome the blood-brain barrier and...
Researchers at the University of Missouri have developed a new imaging probe that can help surgeons accurately identify and remove aggressive brain tumors during operations. The tool, known as FA-ICG, uses near-infrared light to highlight tumor cells from within.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers at Virginia Tech's Fralin Biomedical Research Institute are developing more precise treatments for pediatric brain cancer, specifically glioblastoma, by targeting cancer cells while sparing healthy tissue. The new therapies aim to deliver compounds more effectively to tumor sites using low-intensity focused ultrasound.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.
Researchers at Virginia Tech's Fralin Biomedical Research Institute developed a peptide therapy called JM2 that targets cancer cells' ability to renew and regrow. The treatment significantly slows tumor growth in animal models and disrupts the maintenance of treatment-resistant cancer cells.
Researchers have identified FAM111B as a promising candidate for glioma treatment. The study found that FAM111B overexpression enhances glioma malignancy through the PI3K/AKT pathway, providing a novel avenue for therapeutic intervention.
Researchers discovered a novel mechanism by which glioblastoma cells exploit astrocytes to evade immune responses. The study highlights an astrocyte-driven mechanism used by GBM to escape protective immune responses and could guide novel immunotherapies for the treatment of this aggressive brain cancer.
A new ultra-rapid genetic test has been developed to diagnose brain tumors in under two hours, cutting the current wait time of 6-8 weeks. The test uses Oxford Nanopore Technologies portable sequencing devices and achieves a 100% success rate.
A study by Mass General Brigham found that patients with glioblastoma who received gabapentin lived longer than those who didn't. The medication was shown to confer a four-month survival benefit, with patients on gabapentin surviving an average of 16 months compared to 12 months for those without the drug.
Researchers have developed a new compound, SHP1705, that selectively attacks glioblastoma stem cells by hijacked circadian clock proteins. The compound was found to be safe and well-tolerated in humans during a phase 1 clinical trial.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
Researchers at Ohio State University have identified new targeted therapies for treating small cell lung cancer, predicting melanoma spread, and reducing endometrial cancer risk. A 31-gene expression profile has been developed to identify patients at high risk of melanoma spread, allowing for closer monitoring and earlier treatment.
Researchers at Michigan Medicine have created nanodiscs that can target cholesterol levels in glioblastoma, starving cancer cells and increasing survival rates of treated mice. The combined treatment with radiation therapy was able to preserve normal brain structure and elicited an immunological memory.
Researchers have found that targeting PGM3 can help stop the growth of glioblastoma, a fast-growing brain tumor. By blocking this enzyme, tumors can be effectively suppressed.
Researchers found that combining imipridones with radiation therapy and temozolomide slowed glioblastoma growth and prolonged survival in mice. The treatment also boosted immune responses and suppressed MGMT protein expression, making it more effective.
A recent study reveals that high-mobility group nucleosomal-binding domain 2 (HMGN2) plays a crucial role in glioma progression and serves as a potential biomarker for predicting prognosis. HMGN2 regulates cell cycle progression by binding to histones, enhancing transcriptional activity of proliferation-related genes such as CDC20.
Researchers at UT Health San Antonio have discovered a way to delay or even block recurrence of the deadliest brain cancer after radiation by targeting senescent cells with experimental 'senolytic' drugs. This approach shows promise in preventing tumor growth and improving patient survival.
Researchers analyzed trends in efficacy endpoints for glioblastoma phase II clinical trials, finding a shift towards using time-to-event measures like progression-free survival (PFS) and overall survival (OS). This trend reflects the complexity of GBM treatment evaluation and may indicate evolving clinical trial design.
Researchers identified the prion protein as a key player in the progression of glioblastoma, a type of brain tumor. The study found that blocking the production of this protein using genetic editing reduced the ability of tumor stem cells to proliferate and invade tissues.
Researchers found that suppressing ZNF638 triggers an antiviral immune response in glioblastoma patients, making them more susceptible to treatment. This finding offers a potential new treatment strategy for the disease, which has remained challenging despite recent advances in immunotherapy.
A new drug formulation called Rhenium Obisbemeda has been shown to significantly extend the median survival and progression-free time of glioblastoma patients, with a median overall survival time of 17 months. The treatment, which uses convection-enhanced delivery, shows promise as a potential cure for this deadly brain tumor.
A new study reveals that radiotherapy has opposite effects on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), with GBM patients living longer after treatment. The study highlights the need for personalized treatment approaches based on genetic and molecular characteristics to improve survival outcomes.
Researchers discover engineered TIMP molecules can block cancer cell migration and invasion, offering a targeted approach to treating GBM. The findings also suggest the potential for safe treatment with minimal side effects.